(April 14, 2015) -- The Federal Trade Commission gave final approval to Novartis’ divesting of assets related to its BRAF- and MEK-inhibitor drugs to satisfy the agency’s concerns that the drugmaker’s $16 billion acquisition of GlaxoSmithKline’s cancer treatment drugs would be anticompetitive....